Resolution to authorise the Board of Directors to resolve on directed issue, and issue in kind, of shares

It was resolved to authorise the Board of Directors to, for the period until the end of the Annual general Meeting 2024, on one or more occasions, with or without deviation from the shareholders' preferential rights, resolve on (i) a directed share issue of a maximum of 9,000,000 shares, or the equivalent of SEK 45 million and (ii) an issue in kind of a maximum of 9,000,000 shares, or the equivalent of SEK 45 million. The reasons for the deviation from the shareholders' preferential rights are (i) that the company shall be able to fulfil its obligations under the binding term sheet, entered into between the company and the sellers of Ultinous on 28 February 2024, and (ii) that a prerequisite for the company to be able to carry out the acquisition of Ultinous, is that the company pays payment of the purchase price through the issuance of own shares to the sellers. The subscription price for the respective share issue above, has been determined through negotiations between the company and the sellers of Ultinous, whereby the Board of Directors' assessment is that the subscription price is on market terms.

19 March 2024

Bulletin from Extraordinary General Meeting in Irisity AB (publ)

The following resolutions were passed at the Extraordinary General Meeting of Irisity AB (publ) held today on 19 March 2024 in Gothenburg, Sweden.

Resolution to authorise the Board of Directors to resolve on directed issue, and issue in kind, of shares

It was resolved to authorise the Board of Directors to, for the period until the end of the Annual general Meeting 2024, on one or more occasions, with or without deviation from the shareholders' preferential rights, resolve on (i) a directed share issue of a maximum of 9,000,000 shares, or the equivalent of SEK 45 million and (ii) an issue in kind of a maximum of 9,000,000 shares, or the equivalent of SEK 45 million. The reasons for the deviation from the shareholders' preferential rights are (i) that the company shall be able to fulfil its obligations under the binding term sheet, entered into between the company and the sellers of Ultinous on 28 February 2024, and (ii) that a prerequisite for the company to be able to carry out the acquisition of Ultinous, is that the company pays payment of the purchase price through the issuance of own shares to the sellers. The subscription price for the respective share issue above, has been determined through negotiations between the company and the sellers of Ultinous, whereby the Board of Directors' assessment is that the subscription price is on market terms.

Election of Chairman of the Board of Directors

The Nomination Committee's proposal regarding election of a new Chairman of the Board of Directors, as set forth in the convening notice, was, prior to the Extraordinary General Meeting, revoked due to the fact that the reasons that were presented no longer exist. Whereby Ulf Runmarker will remain Chairman of the Board of Directors for the period until the end of the Annual General Meeting 2024.

For more information, please contact:

Keven Marier, CEO, Irisity AB, +46 771 41 11 00, keven.marier@irisity.com.

The information was submitted for publication, through the agency of the contact person set out above, at 15:30 CET on 19 March 2024.

About Irisity

Irisity AB (publ) is a world-leader in AI-powered video analytics solutions for enhanced safety and security. As of October 13, 2021, Agent Vi is part of Irisity. Founded in 2006, Irisity has offices in Sweden (HQ), Israel, USA, Singapore, UAE, Colombia, Brazil, Argentina, Australia and the United Kingdom. The company is serving a network of integrators, distributors, and technology partners globally.

The Irisity AB (publ) share is listed on Nasdaq First North Growth Market, with the ticker IRIS, the company's Certified Adviser is Carnegie Investment Bank AB (publ), certifiedadviser@carnegie.se.

https://news.cision.com/irisity-ab/r/bulletin-from-extraordinary-general-meeting-in-irisity-ab--publ-,c3948333

https://mb.cision.com/Main/8006/3948333/2679604.pdf

(c) 2024 Cision. All rights reserved., source Press Releases - English